Vivek Subbiah: Another FDA approval to adagrasib plus cetuximab for KRAS G12C-mutated colorectal cancer
Vivek Subbiah shared on LinkedIn:
“It’s Friday and time for another FDA approval!
FDA grants accelerated approval to adagrasib plus cetuximab for KRAS G12C-mutated colorectal cancer.
Link to FDA approval.
Link to NEJM Group publication.”
Source: Vivek Subbiah/LinkedIn
Vivek Subbiah is the Chief of Early-Phase Drug Development at the Sarah Cannon Research Institute (USA).
He is the former Executive Director of Oncology Research and former Associate Professor in the Department of Investigational Cancer Therapeutics at the MD Anderson Cancer He focuses on translational cancer research and the design and implementation of early-phase biomarker-driven clinical trials.
His work specifically targets antibody-drug conjugates, radiopharmaceuticals, immunoconjugates, and basket trials.
